Skip to content

key figures

About Servier

34th

largest pharmaceutical group worldwide

8807A8D1-7910-4193-8E0A-4CE1D5F4F7EF

2nd

largest French pharmaceutical group

8DEC2750-9A76-416E-B850-9D223B9C3E09

20%

Over 20% of revenue from brand-name medicines invested in R&D each year

81B6CC56-77D1-4E8F-B1D9-1F35D75852DE

70

Over 70 scientific partnerships and collaborations in 2020/2021

FA69FF45-BE0A-490D-90AF-C6C4E8B4670D

21,800

employees

7F95C559-D02F-4313-B3DB-128F9F3E1DDA

98%

of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France

7FE8EEA1-7D1F-4BE7-9FC4-68BA35956D1C

19

Collaborations with 19 international patient organizations in 2020/2021

Driving scientific and medical progress

4

therapeutic areas: oncology, cardiometabolism, neuroscience and immuno-inflammation

39

projects in clinical development (including 17 new molecular entities) and 34 research projects (September 2022)

3rd

leading pharmaceutical group in cardiology worldwide

3rd

leading pharmaceutical group in hypertension worldwide

Global presence

150

Over 150 countries where the Group’s medicines are distributed

16

production sites

6

research centers

15

International Centers for Therapeutic Research

1

network for external innovation

Social responsibility

-25%

Target to reduce CO2 emissions by 25% by 2030

40%

Target to appoint women to at least 40% of senior management positions within the Servier Group by 2024

4.23/5

Overall engagement score achieved by the Servier Group

Financial performance

4.7

billion in revenue in 2020/2021

(including €3.3 billion for brand-name medicines and €1.4 billion for generic activities)

625

million in EBITDA in 2020/2021

[1] IQVIA, Analytics Link / World 74 countries – MAT Q1-2022
[2] Source: annual engagement survey conducted with the Gallup Institute – 2022 Group results